Generic Viberzi Availability

Last updated on Jun 11, 2025.

Viberzi is a brand name of eluxadoline, approved by the FDA in the following formulation(s):

VIBERZI (eluxadoline - tablet;oral)

• Manufacturer: ABBVIE
  Approval date: May 27, 2015
  Strength(s): 75MG ^{[RLD] [AB]}, 100MG ^{[RLD] [AB]}

Is there a generic version of Viberzi available?

A generic version of Viberzi has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Viberzi and have been approved by the FDA:

eluxadoline tablet;oral

• Manufacturer: ZYDUS PHARMS
  Approval date: March 14, 2025
  Strength(s): 75MG ^[AB], 100MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viberzi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Opioid receptor modulator dosage formulations
  Patent 10,188,632
  Issued: January 29, 2019
  Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
  Assignee(s): Allergan Holdings Unlimited Company
  

  Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

  Patent expiration dates:

  • March 14, 2033
    
    ✓ 
    Drug product
• Compounds as opioid receptor modulators
  Patent 10,213,415
  Issued: February 26, 2019
  Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
  Assignee(s): Janssen Pharmaceutica NV
  

  The present invention is directed to novel opioid receptor modulators of Formula (I).

  Patent expiration dates:

  • March 14, 2025
    
    ✓ 
    Patent use: TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
    ✓ 
    Drug substance
• Opioid receptor modulator dosage formulations
  Patent 11,007,179
  Issued: May 18, 2021
  Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
  Assignee(s): Allergan Holdings Unlimited Company
  

  Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

  Patent expiration dates:

  • March 14, 2033
    
    ✓ 
    Drug product
• Opioid receptor modulator dosage formulations
  Patent 11,090,291
  Issued: August 17, 2021
  Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
  Assignee(s): Allergan Holdings Unlimited Company
  

  Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

  Patent expiration dates:

  • March 14, 2033
    
    ✓ 
    Drug product
• Opioid receptor modulator dosage formulations
  Patent 11,160,792
  Issued: November 2, 2021
  Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
  Assignee(s): Allergan Holdings Unlimited Company
  

  Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

  Patent expiration dates:

  • March 14, 2033
    
    ✓ 
    Drug product
• Opioid receptor modulator dosage formulations
  Patent 11,229,627
  Issued: January 25, 2022
  Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
  Assignee(s): Allergan Holdings Unlimited Company
  

  Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

  Patent expiration dates:

  • March 14, 2033
    
    ✓ 
    Drug product
• Opioid receptor modulator dosage formulations
  Patent 11,311,516
  Issued: April 26, 2022
  Inventor(s): Costello; Tim et al.
  Assignee(s): Allergan Holdings Unlimited Company (Dublin, IE)
  

  Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

  Patent expiration dates:

  • March 14, 2033
    
    ✓ 
    Drug product
• Opioid receptor modulator dosage formulations
  Patent 11,484,527
  Issued: November 1, 2022
  Inventor(s): Costello; Tim et al.
  Assignee(s): Allergan Holdings Unlimited Company (Dublin, IE)
  

  Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

  Patent expiration dates:

  • March 14, 2033
    
    ✓ 
    Patent use: REDUCTION OF THE FREQUENCY OF ABDOMINAL PAIN AND DIARRHEA, IN AN INFLAMMATORY BOWEL DISEASE WITH DIARRHEA (IBS-D) PATIENT, WITH ELUXADOLINE TWICE DAILY WITH FOOD
• Opioid receptor modulator dosage formulations
  Patent 12,097,187
  Issued: September 24, 2024
  Inventor(s): Costello; Tim et al.
  Assignee(s): Allergan Holdings Unlimited Company (Dublin, IE)
  

  Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6 -dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy -benzoic acid, and processes for the preparation and administration of these formulations.

  Patent expiration dates:

  • March 14, 2033
    
    ✓ 
    Patent use: REDUCTION OF THE FREQUENCY OF ABDOMINAL PAIN AND DIARRHEA, IN AN INFLAMMATORY BOWEL DISEASE WITH DIARRHEA (IBS-D) PATIENT, WITH ELUXADOLINE TWICE DAILY WITH FOOD
• Compounds as opioid receptor modulators
  Patent 7,741,356
  Issued: June 22, 2010
  Inventor(s): Breslin; Henry J. et al.
  Assignee(s): Janssen Pharmaceutica N.V. (Beerse, BE)
  

  The present invention is directed to novel opioid receptor modulators of Formula (I). ##STR00001## The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.

  Patent expiration dates:

  • May 27, 2029
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Compounds as opioid receptor modulators
  Patent 7,786,158
  Issued: August 31, 2010
  Inventor(s): Breslin; Henry J. et al.
  Assignee(s): Janssen Pharmaceutica N.V. (Beerse, BE)
  

  The present invention is directed to novel opioid receptor modulators of Formula (I). ##STR00001## The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.

  Patent expiration dates:

  • March 14, 2025
    
    ✓ 
    Drug substance
• Compounds as opioid receptor modulators
  Patent 8,344,011
  Issued: January 1, 2013
  Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
  Assignee(s): Janssen Pharmaceutica, N.V.
  

  The present invention is directed to novel opioid receptor modulators of Formula (I).

  Patent expiration dates:

  • March 14, 2025
    
    ✓ 
    Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
• Compounds as opioid receptor modulators
  Patent 8,609,709
  Issued: December 17, 2013
  Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
  Assignee(s): Janssen Pharmaceutica, N. V.
  

  The present invention is directed to novel opioid receptor modulators of Formula (I).

  Patent expiration dates:

  • March 14, 2025
    
    ✓ 
    Drug substance
• Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
  Patent 8,691,860
  Issued: April 8, 2014
  Inventor(s): Anzalone Luigi & Villani Frank J. & Teleha Christopher A. & Feibush Penina & Fegely Barry
  Assignee(s): Furiex Pharmaceuticals, Inc.
  

  The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.

  Patent expiration dates:

  • July 7, 2028
    
    ✓ 
    Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
    ✓ 
    Drug substance
• Compounds as opioid receptor modulators
  Patent 8,772,325
  Issued: July 8, 2014
  Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
  Assignee(s): Janssen Pharmaceutica, N.V.
  

  The present invention is directed to novel opioid receptor modulators of Formula (I).

  Patent expiration dates:

  • March 14, 2025
    
    ✓ 
    Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
• Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
  Patent 9,115,091
  Issued: August 25, 2015
  Inventor(s): Anzalone Luigi & Villani Frank J. & Teleha Christopher A. & Feibush Penina & Fegely Barry
  Assignee(s): FURIEX PHARMACEUTICALS, INC.
  

  The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.

  Patent expiration dates:

  • July 7, 2028
    
    ✓ 
    Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Compounds as opioid receptor modulators
  Patent 9,205,076
  Issued: December 8, 2015
  Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
  Assignee(s): Janssen Pharmaceutica, N.V.
  

  The present invention is directed to novel opioid receptor modulators of Formula (I).

  Patent expiration dates:

  • March 14, 2025
    
    ✓ 
    Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
• Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
  Patent 9,364,489
  Issued: June 14, 2016
  Inventor(s): Anzalone Luigi & Villani Frank J. & Teleha Christopher A. & Feibush Penina & Fegely Barry
  Assignee(s): Forest Tosara Limited
  

  The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.

  Patent expiration dates:

  • July 7, 2028
    
    ✓ 
    Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
• Opioid receptor modulator dosage formulations
  Patent 9,675,587
  Issued: June 13, 2017
  Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
  Assignee(s): Allergan Holdings Unlimited Company
  

  Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

  Patent expiration dates:

  • March 14, 2033
    
    ✓ 
    Drug product
• Compounds as opioid receptor modulators
  Patent 9,700,542
  Issued: July 11, 2017
  Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
  Assignee(s): Janssen Pharmaceutica NV
  

  The present invention is directed to novel opioid receptor modulators of Formula (I).

  Patent expiration dates:

  • March 14, 2025
    
    ✓ 
    Drug product
• Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
  Patent 9,789,125
  Issued: October 17, 2017
  Inventor(s): Anzalone Luigi & Villani Frank J. & Teleha Christopher A. & Feibush Penina & Fegely Barry
  Assignee(s): Allergan Holdings Unlimited Company
  

  The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.

  Patent expiration dates:

  • July 7, 2028
    
    ✓ 
    Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
    ✓ 
    Drug product
  • July 7, 2028
    
    ✓ 
    Patent use: TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
    ✓ 
    Drug product

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer